Want to see CORT full AI Analyst Report?
CORT Stock Chart & Stats
$46.16
$0.08(0.16%)
At close: 4:00 PM EST
$46.16
$0.08(0.16%)
Day’s Range― - ―
52-Week Range$28.66 - $91.00
Previous CloseN/A
Volume78.39K
Average Volume (3M)1.09M
Market Cap
$9.68B
Enterprise Value$8.68B
Total Cash (Recent Filing)$338.18M
Total Debt (Recent Filing)$9.64M
Price to Earnings (P/E)200.5
Beta0.47
Next Earnings
Aug 05, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.45
Shares Outstanding107,351,590
10 Day Avg. Volume1,049,587
30 Day Avg. Volume1,093,467
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)5.58
Price to Sales (P/S)4.75
P/FCF Ratio25.49
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue11.28
Enterprise Value/Gross Profit11.48
Enterprise Value/Ebitda612.95
Forecast
1Y Price Target
$97.50Price Target Upside111.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.59
Revenue Forecast (FY)$976.58M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And Cash RunwayA large cash balance and minimal debt provide durable financial flexibility to fund launches, clinical programs and commercialization without near-term refinancing risk. This supports multi-year investment in oncology and endocrine expansion even if near-term profits fluctuate.
Lifyorli Approval With Meaningful Survival BenefitA confirmatory survival benefit and FDA approval create a durable competitive advantage in platinum‑resistant ovarian cancer, supporting inclusion in guidelines and long-term uptake. This establishes a new oncology revenue stream distinct from legacy endocrine sales.
Clinical Data Expanding Addressable Endocrine MarketRobust epidemiology and guideline‑referenced trial data imply materially larger screening and treatment pools. Structural increases in diagnosis and treatment rates can sustain multi-year growth for Korlym and future hypercortisolism therapies.
Bears Say
Eroding Profitability And Weaker Cash MomentumFalling margins and a quarter with a net loss signal pressure on earnings conversion from high gross margins to lower net profitability. If margin compression persists it can reduce reinvestment capacity and elevate reliance on cash reserves during heavy launch spending.
Ongoing Legal Uncertainty From Amended Qui Tam SuitProtracted whistleblower litigation creates persistent legal and reputational risk, potential for settlements or remediation, and distraction for management. Even without immediate government intervention, the case can affect reimbursement scrutiny and long‑term commercial dynamics.
Operational And Tolerability Risks Could Constrain ScalingLogistics bottlenecks, prior‑authorization backlogs and tolerability‑related discontinuations in DAZALS risk interrupting patient flow and revenue conversion. Operational missteps during rapid launch scale can slow commercial momentum and raise incremental support costs.
Corcept Therapeutics News
CORT FAQ
What was Corcept Therapeutics’s price range in the past 12 months?
Corcept Therapeutics lowest stock price was $28.66 and its highest was $91.00 in the past 12 months.
What is Corcept Therapeutics’s market cap?
Corcept Therapeutics’s market cap is $9.68B.
When is Corcept Therapeutics’s upcoming earnings report date?
Corcept Therapeutics’s upcoming earnings report date is Aug 05, 2026 which is in 30 days.
How were Corcept Therapeutics’s earnings last quarter?
Corcept Therapeutics released its earnings results on Apr 30, 2026. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.19.
Is Corcept Therapeutics overvalued?
According to Wall Street analysts Corcept Therapeutics’s price is currently Undervalued.
Does Corcept Therapeutics pay dividends?
Corcept Therapeutics does not currently pay dividends.
What is Corcept Therapeutics’s EPS estimate?
Corcept Therapeutics’s EPS estimate is 0.01.
How many shares outstanding does Corcept Therapeutics have?
Corcept Therapeutics has 107,351,590 shares outstanding.
What happened to Corcept Therapeutics’s price movement after its last earnings report?
Corcept Therapeutics reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went up 10.533%.
Which hedge fund is a major shareholder of Corcept Therapeutics?
Currently, no hedge funds are holding shares in CORT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corcept Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$97.50 (111.22% Upside)
$97.50 (111.22% Upside)
Blogger Sentiment
Bullish
CORT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 127.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.45%
12-Months-Change
Fundamentals
Return on Equity
7.50%
Trailing 12-Months
Asset Growth
-3.73%
Trailing 12-Months
Company Description
Corcept Therapeutics
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
CORT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum driven by major clinical and regulatory milestones (Lifyorli FDA approval with a significant survival benefit, landmark CATALYST and MOMENTUM findings that broaden the addressable market, robust patient and prescriber growth, raised 2026 guidance, and compelling ALS and MASH data). Near-term negatives include a Q1 earnings swing to a net loss, temporary revenue headwinds from insurance reauthorizations and a pharmacy-transition backlog, and tolerability-related discontinuations in DAZALS that require mitigation. On balance, the company demonstrated durable commercial traction, an expanding pipeline with high-impact results, and clear plans to address operational issues, leading to a favorable outlook.View all CORT earnings summariesCORT Stock 12 Month Forecast
Average Price Target
$97.50
▲(111.22% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
Legend Biotech
―
Ownership Overview
10.88% Insiders
15.08% Mutual Funds
<0.01% Other Institutional Investors
52.64% Public Companies and
Individual Investors